RNAZ on Nasdaq
Transcode Therapeutics, Inc.
TransCode is a clinical-stage company pioneering immuno-oncology and RNA therapeutics for treatment of high risk and advanced cancers.3 From its latest annual report
Price unavailable
Last updated Oct 19, 2026.
Overview
- TickerRNAZ on Nasdaq1
- IndustryPharmaceutical Preparations1
- HeadquartersBoston, Massachusetts1
- Incorporated inDE2
- Business address6 Liberty Square, #2382, Boston, Ma 021092
- Filer category, Emerging growth company2
- Legal formCorporation
See how the biggest companies compare on our leaderboards
TransCode is a clinical-stage company pioneering immuno-oncology and RNA therapeutics for treatment of high risk and advanced cancers. Our lead therapeutic product candidate is TTX-MC138, an antisense inhibitor of an oncogenic microRNA. TTX-MC138 has recently completed a Phase 1a clinical trial. In addition to other RNA-targeted product candidates, we are conducting research and development of a cancer vaccine product candidate and an oncolytic immunotherapy platform.3 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Research and development | $284.5K4 | $2.8M5 | $10.2M6 | $12.3M7 | $9.7M8 | $13.4M8 | ||
| Operating expenses | $6.2M5 | $18.6M6 | $19.4M7 | $15.7M8 | $28.0M8 | |||
| Operating income | -$726.6K4 | -$6.2M5 | -$18.6M6 | -$19.4M7 | -$15.7M8 | -$28.0M8 | ||
| Interest | $394.6K4 | $95.1K5 | $32.0K6 | $55.9K7 | $26.8K7 | |||
| Income before tax | -$16.8M8 | -$34.4M8 | ||||||
| Income tax | $04 | $53.1K5 | $06 | $07 | $08 | $226.1K8 | ||
| Net income | -$2.3M4 | -$6.8M5 | -$17.6M6 | -$18.5M7 | -$16.8M8 | -$34.7M8 | ||
| Earnings per share | -$0.514 | -$0.815 | -$1,082.796 | -$3,419.017 | -$1,336.638 | -$52.598 | ||
| Earnings per share (diluted) | -$0.514 | -$0.815 | -$1,082.796 | -$3,419.017 | -$1,336.638 | -$52.598 | ||
| Shares (weighted, basic) | 8.4M shares5 | 16.2K shares6 | 5.4K shares7 | 12.6K shares8 | 689.7K shares8 | |||
| Shares (weighted, diluted) | 8.4M shares5 | 16.2K shares6 | 5.4K shares7 | 12.6K shares8 | 689.7K shares8 |
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash | $204.5K4 | $828.0K4 | $20.8M5 | $5.0M6 | $2.8M7 | $5.8M8 | $17.8M8 | |
| Current assets | $831.2K4 | $22.7M5 | $7.4M6 | $4.5M7 | $7.1M8 | $22.0M8 | ||
| Property, plant and equipment | $206.3K5 | $208.6K6 | $120.7K7 | $51.6K8 | $370.7K8 | |||
| Goodwill | $25.7M8 | |||||||
| Intangible assets | $114.3M8 | |||||||
| Total assets | $1.1M4 | $22.9M5 | $7.6M6 | $5.2M7 | $7.3M8 | $162.4M8 | ||
| Current liabilities | $404.9K4 | $2.5M5 | $4.3M6 | $3.5M7 | $2.8M8 | $3.5M8 | ||
| Long-term liabilities | $38.3K7 | $6.5M8 | $7.0M8 | |||||
| Total liabilities | $4.5M4 | $2.5M5 | $4.3M6 | $3.5M7 | $9.3M8 | $10.5M8 | ||
| Retained earnings | -$10.3M5 | -$27.9M6 | -$46.4M7 | -$63.2M8 | -$97.9M8 | |||
| Shareholders’ equity | -$1.1M4 | -$3.4M5 | $20.4M6 | $3.2M7 | $1.6M8 | -$2.0M8 | $10.3M8 | |
| Shares outstanding | 4.6M shares4 | 12.9M shares5 | 16.2K shares6 | 19.0K shares7 | 36.8K shares8 | 917.0K shares8 | 917.0K shares11 |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -$493.0K4 | -$5.3M5 | -$15.8M6 | -$18.1M7 | -$13.3M8 | -$19.5M8 | ||
| Depreciation and amortization | $42.5K5 | $98.6K6 | $123.5K7 | $90.9K8 | $13.4K9 | |||
| Stock-based compensation | $186.0K5 | $395.3K6 | $1.0M7 | $1.7M8 | $485.4K8 | |||
| Capital spending | $254.8K5 | $100.9K6 | $35.6K7 | $21.8K8 | $6.7K8 | |||
| Free cash flow | -$5.5M | -$15.9M | -$18.1M | -$13.4M | -$19.5M | |||
| Cash from investing | -$251.8K5 | -$100.9K6 | -$35.6K7 | -$21.8K8 | -$4.4K8 | |||
| Cash from financing | $25.5M5 | $6.0K6 | $15.9M7 | $16.4M8 | $31.5M8 |
Leadership
Who has led Transcode Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
- Chief executive officerThomas A. Fitzgerald Jun 18, 2024 to Jun 18, 202412
- Chief financial officerJohn A. Tattory Sep 21, 2026 to now13
- Chief financial officerThomas A. Fitzgerald Jul 8, 2021 to Sep 21, 202614
Board members and other officers (7)
- Chief Technology OfficerZdravka Medarova Dec 14, 2022 to Dec 14, 202215
- Board memberElizabeth Czerepak Dec 22, 2025 to now16
- Board memberJack E. Stover Dec 22, 2025 to now17
- Board memberErik Manting Jul 8, 2021 to Jun 18, 202418
- Board memberMagda Marquet Jul 8, 2021 to Jun 18, 202419
- Board memberPhilippe Calais Jul 8, 2021 to Jun 18, 202420
- Board memberThomas A. Fitzgerald Jul 8, 2021 to now14
Timeline
- Jun 18, 2024New chief executive Thomas A. Fitzgerald becomes CEO12
Filings
282 filings to the SEC since October 2021: 7 annual reports, 15 quarterly reports, 84 major events, 36 insider forms, 32 large holders, 1 private raises, 107 other. The latest 20:
- Oct 1, 20268-K EDGAR
- Sep 28, 20268-K EDGAR
- Sep 21, 20263 OWNERSHIP DOCUMENT EDGAR
- Sep 11, 20264 OWNERSHIP DOCUMENT EDGAR
- Sep 11, 20268-K EDGAR
- Aug 14, 202610-Q EDGAR
- Aug 5, 20264 OWNERSHIP DOCUMENT EDGAR
- Aug 5, 20263 OWNERSHIP DOCUMENT EDGAR
- Aug 3, 2026SCHEDULE 13D/A EDGAR
- Aug 3, 20268-K EDGAR
- Jul 28, 2026SCHEDULE 13G EDGAR
- Jul 28, 2026SCHEDULE 13G EDGAR
- Jul 28, 2026SCHEDULE 13G EDGAR
- Jul 27, 2026SCHEDULE 13D/A EDGAR
- Jul 23, 2026SCHEDULE 13D/A EDGAR
- Jul 20, 2026424B3 EDGAR
- Jul 20, 2026424B3 EDGAR
- Jul 20, 20268-K EDGAR
- Jul 17, 2026SCHEDULE 13D/A EDGAR
- Jul 17, 2026DEFA14A EDGAR
The 282 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
10 open-market trades by officers, directors and large owners since October 2021: 10 buys and 0 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 28, 2023 | Fitzgerald Thomas AChief Financial Officer | Buy | 49,350 | $0.51 | $25.2K | Form 4 |
| Sep 28, 2023 | Dudley Robert MichaelChief Executive Officer | Buy | 98,000 | $0.51 | $50.0K | Form 4 |
| Jun 21, 2023 | Dudley Robert MichaelChief Executive Officer | Buy | 12,000 | $2.65 | $31.8K | Form 4 |
| Jun 20, 2023 | Dudley Robert MichaelChief Executive Officer | Buy | 6,607 | $2.55 | $16.8K | Form 4 |
| Jun 9, 2023 | Dudley Robert MichaelChief Executive Officer | Buy | 19,000 | $2.76 | $52.4K | Form 4 |
| Jun 9, 2023 | Dudley Robert MichaelChief Executive Officer | Buy | 19,000 | $2.76 | $52.4K | Form 4 |
| Sep 14, 2022 | Dudley Robert MichaelChief Executive Officer | Buy | 20,000 | $1.15 | $23.0K | Form 4 |
| Jun 16, 2022 | Fitzgerald Thomas AChief Financial Officer | Buy | 12,000 | $1.27 | $15.2K | Form 4 |
| May 31, 2022 | Dudley Robert MichaelChief Executive Officer | Buy | 2,000 | $1.87 | $3.7K | Form 4 |
| May 27, 2022 | Dudley Robert MichaelChief Executive Officer | Buy | 28,000 | $1.84 | $51.5K | Form 4 |
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- CK Life Sciences Intl (Holdings) IncSCHEDULE 13D/A, 6 filings Oct 16, 2025 to Aug 3, 202621
- Daniel Eduardo KatzmanSCHEDULE 13G, 1 filing Jul 28, 202622
- Elena Rosa BraciSCHEDULE 13G, 1 filing Jul 28, 202623
- Unleash Immuno Oncolytics, Inc.SCHEDULE 13G, 1 filing Jul 28, 202624
- YA II PN, Ltd.SCHEDULE 13G, 1 filing Apr 20, 202625
- SABBY MANAGEMENT, LLCSCHEDULE 13G/A, 2 filings Jan 3, 2025 to Jan 7, 202626
- Goldman SachsSCHEDULE 13G/A, 1 filing Nov 10, 202527
- Anson Funds Management LPSCHEDULE 13G/A, 2 filings Feb 14, 2025 to Aug 14, 202528
- Thomas Joseph TracySCHEDULE 13D, 1 filing Mar 20, 202529
- 3i, LPSC 13G/A, 2 filings Jul 26, 2024 to Nov 6, 202430
- Thomas A. FitzgeraldSC 13D, 1 filing Jun 21, 202431
- Zdravka MedarovaSC 13G/A, 3 filings Dec 20, 2022 to Feb 15, 202432
- TANG CAPITAL PARTNERS LPSC 13G/A, 2 filings Sep 26, 2023 to Feb 14, 202433
- Lind Global Fund II LPSC 13G/A, 2 filings Dec 7, 2023 to Feb 13, 202434
- Robert Michael DudleySC 13D/A, 4 filings Dec 20, 2022 to Oct 10, 202335
- Orin HirschmanSC 13G/A, 2 filings Feb 11, 2022 to Oct 27, 202236
Money raised
Private offerings the company reported to the SEC on Form D.
- Dec 2, 2024Raised $8 million in a private offering of equity Form D: 6 investors so far Form D
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Yorkville Advisors Global, LP | 19,639 | $122.0K | 0.1% | New |
| Vanguard Capital Management LLC | 6,545 | $40.6K | 0.0% | No change |
| Vanguard Fiduciary Trust Co | 2,982 | $18.5K | 0.0% | No change |
| UBS Group AG | 2,888 | $17.9K | 0.0% | −5,407 |
| Fmr LLC | 706 | $4.4K | 0.0% | New |
| Tower Research Capital LLC (TRC) | 677 | $4.2K | 0.0% | +449 |
| Wells Fargo & Company/mn | 55 | $342 | 0.0% | No change |
| SBI Securities Co., Ltd. | 12 | $75 | 0.0% | No change |
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16SEC EDGARElizabeth Czerepak, Board member
- 17SEC EDGARJack E. Stover, Board member
- 18SEC EDGARErik Manting, Board member
- 19SEC EDGARMagda Marquet, Board member
- 20SEC EDGARPhilippe Calais, Board member
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36